Comparison of olanzapine and haloperidol and quetiapine on delirium

Comparison of the effect of Olanzapine and Haloperidol and quetiapine on the Treatment of delirium in Intensive care unit (ICU) patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200927048852N1

Enrollment

Registered

2020-10-13

Start date

2020-10-22

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium. Delirium due to known physiological condition

Interventions

Intervention 1: First intervention group: In the first group, patients with delirium receive haloperidol (Sobhan Daru Company - Iran) at a dose of 2.5 mg per day, once daily and orally for 10 days unt

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients who have been diagnosed with delirium by the 5th edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria and have suffered a brain injury

Exclusion criteria

Exclusion criteria: primary neurological diseases such as stroke, dementia, psychosis pregnancy and lactation modified QT interval more than 440 milliseconds

Design outcomes

Primary

Measure	Time frame
Sedation. Timepoint: Before the intervention and the third, seventh and tenth days after the intervention. Method of measurement: Richmond Agitation and Sedation Scale.;Illness severity. Timepoint: Before the intervention and the third, seventh and tenth days after the start of the intervention. Method of measurement: Acute Physiology and Chronic Health Evaluation II.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohamad Eslami

Arak University of Medical Sciences

daneshkadeha@arakmu.ac.ir+98 86 3417 3520

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026